BrainAurora-B's stock plummeted 6.34% during intraday trading on Wednesday, marking a significant decline following recent volatility.

The drop appears to be a pullback after the stock surged as much as 50% in the prior session. That rally was driven by news that China officially launched its first 128-channel fully implanted brain-computer interface (BCI) system multi-center clinical trial, marking a milestone in the country's self-developed fully invasive BCI technology entering the clinical translation stage.

The BCI industry is at a critical juncture transitioning from laboratory breakthroughs to commercial deployment, with market scale potentially expanding significantly in the long term, which has contributed to the heightened investor interest and subsequent volatility in BrainAurora-B shares.